Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts.
Affiliation
Cancer Research Campaign Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, UK. mmiddleton@picr.man.ac.ukIssue Date
2000
Metadata
Show full item recordAbstract
PURPOSE: To establish whether temozolomide is more effective against A375M human melanoma xenografts if given every 4 h rather than every 24 h, in order to exploit depletion of the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase) by prior doses of the drug. METHODS: ATase depletion in A375M human melanoma xenografts was determined over 24 h after a single dose of temozolomide. The effect of different drug schedules (all of total dose 500 mg/kg) in delaying the growth of the xenografts was tested, and ATase depletion and DNA methylation damage assessed in tumour and normal tissue. RESULTS: Maximal depletion of ATase in tumour, to 2.52 +/- 0.23% of pretreatment levels, occurred 4-8 h after a single 100 mg/kg i.p. dose of temozolomide, with 23.0% recovery of protein levels at 24 h. Scheduling of temozolomide every 4 h increased tumour growth delay (33.6 +/- 1.39 days with temozolomide 100 mg/kg 4-hourly x versus 23.2 +/- 1.43 days with temozolomide 100 mg/kg once daily x 5; P < 0.0001) at the expense of increased toxicity (17.4 +/- 1.55% animal weight loss versus 10.6 +/- 1.27%. respectively). Temozolomide every 4 h did not increase ATase depletion compared with the 5-day schedule, but resulted in greater DNA 06-guanine methylation (29.0% more in tumour, 20.8% in liver and 56.0% in brain, comparing areas under the methylation-time curve). CONCLUSIONS: The 4-hourly schedule of temozolomide delayed tumour growth significantly more than the once-daily and 12-hourly schedules, probably as a result of greater DNA damage inflicted, but also increased toxicity. It remains to be seen if this regimen confers a net benefit over the standard schedule.Citation
Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts. 2000, 45 (1):15-20 Cancer Chemother. Pharmacol.Journal
Cancer Chemotherapy and PharmacologyDOI
10.1007/PL00006737PubMed ID
10647496Type
ArticleLanguage
enISSN
0344-5704ae974a485f413a2113503eed53cd6c53
10.1007/PL00006737
Scopus Count
Related articles
- O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts.
- Authors: Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, McCormick JE, Margison GP
- Issue date: 2000 Jan 15
- Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model.
- Authors: Middleton MR, Thatcher N, McMurry TB, McElhinney RS, Donnelly DJ, Margison GP
- Issue date: 2002 Aug 10
- Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
- Authors: Wedge SR, Porteous JK, Newlands ES
- Issue date: 1997
- Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
- Authors: Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK
- Issue date: 2003 Apr 7
- Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.
- Authors: Lee SM, Thatcher N, Crowther D, Margison GP
- Issue date: 1994 Mar